Drug interactions
Deflazacort + Larotrectinib
Severity: Minor
Deflazacort and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate and a weak CYP3A4 inhibitor in vitro, and deflazacort's active metabolite is cleared by CYP3A4. Exposure to the active metabolite may rise modestly, increasing corticosteroid adverse effects.
What this interaction means in plain words
Deflazacort and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Deflazacort belongs to Miscellaneous; Larotrectinib belongs to Oncology.
Why it happens
Possible weak inhibition of CYP3A4-mediated clearance of the active deflazacort metabolite.
What to do
Monitor for corticosteroid adverse effects such as fluid retention, hyperglycemia and infection. Reduce the deflazacort dose if they occur.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deflazacort and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Deflazacort
- Adenovirus types 4 and 7 live + Deflazacort Contraindicated
- Bcg vaccine live + Deflazacort Contraindicated
- Deflazacort + Influenza virus vaccine quadrivalent intranasal Contraindicated
- Deflazacort + Measles mumps and rubella vaccine Contraindicated
- Deflazacort + Measles mumps and rubella vaccine live Contraindicated
- Deflazacort + Measles mumps rubella and varicella vaccine live Contraindicated
Other interactions of Larotrectinib
Frequently asked questions
Can I take Deflazacort with Larotrectinib?
MediHelp rates the interaction as minor. Deflazacort and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate and a weak CYP3A4 inhibitor in vitro, and deflazacort's active metabolite is cleared by CYP3A4. Exposure to the active metabolite may rise modestly, increasing corticosteroid adverse effects.
How serious is the interaction between Deflazacort and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for corticosteroid adverse effects such as fluid retention, hyperglycemia and infection. Reduce the deflazacort dose if they occur.
What other medicines interact with Deflazacort?
MediHelp also lists interactions of Deflazacort with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal. The full list is on the Deflazacort page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
